Literature DB >> 25039916

MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease.

Bing Zhang1,2, Tanis J Ferman3, Bradley F Boeve4, Glenn E Smith5, Mandie Maroney-Smith1, Anthony J Spychalla1, David S Knopman4, Clifford R Jack1, Ronald C Petersen4, Kejal Kantarci1.   

Abstract

BACKGROUND AND
PURPOSE: Mild cognitive impairment (MCI) precedes both Alzheimer's disease (AD) dementia and with Lewy bodies (DLB). We investigated proton magnetic resonance spectroscopy (MRS) characteristics of MCI patients who progressed to DLB compared to those who progressed to AD dementia or remained stable.
METHODS: Consecutive MCI patients who underwent single voxel MRS at baseline and progressed to DLB (n = 10) were identified during a median follow-up period of 18 months. From the same cohort, we identified age- and sex-matched MCI patients who progressed to AD dementia (n = 27) or remained stable (n = 20) during a similar follow-up period. This study was approved by the Institutional Review Board and informed consent was from every subject.
RESULTS: MCI patients who progressed to AD dementia were characterized by lower N-acetylaspartate (NAA)/Cr ratio in the posterior cingulate voxel compared to those who progressed to DLB (P = .001). Decreased NAA/Cr in the posterior cingulate voxel differentiated MCI patients who progressed to DLB from those who progressed to AD with an area under the receiver operating characteristic curve of .85 (P < .001) on logistic regression analysis.
CONCLUSIONS: MRS may be useful in differentiating MCI patients with prodromal AD dementia from those with prodromal DLB for early disease-specific interventions.
Copyright © 2014 by the American Society of Neuroimaging.

Entities:  

Keywords:  Alzheimer's disease; MRI; Magnetic resonance spectroscopy (MRS); dementia with Lewy Bodies (DLB); mild cognitive impairment (MCI)

Mesh:

Substances:

Year:  2014        PMID: 25039916      PMCID: PMC4295004          DOI: 10.1111/jon.12138

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  45 in total

1.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

2.  Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Authors:  John C Morris
Journal:  Arch Neurol       Date:  2012-06

3.  Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study.

Authors:  T A Ala; K H Yang; J H Sung; W H Frey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

4.  Glucose hypometabolism in primary visual cortex is commonly associated with clinical features of dementia with Lewy bodies regardless of cognitive conditions.

Authors:  Hiroshige Fujishiro; Eizo Iseki; Koji Kasanuki; Norio Murayama; Kazumi Ota; Masaru Suzuki; Kiyoshi Sato
Journal:  Int J Geriatr Psychiatry       Date:  2012-01-17       Impact factor: 3.485

5.  Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies.

Authors:  Tanis J Ferman; Glenn E Smith; Kejal Kantarci; Bradley F Boeve; V Shane Pankratz; Dennis W Dickson; Neill R Graff-Radford; Zbigniew Wszolek; Jay Van Gerpen; Ryan Uitti; Otto Pedraza; Melissa E Murray; Jeremiah Aakre; Joseph Parisi; David S Knopman; Ronald C Petersen
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

6.  Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Melissa E Murray; Tanis J Ferman; Nirubol Tosakulwong; Timothy G Lesnick; Mandie Maroney-Smith; Matthew L Senjem; Jeffrey Gunter; Glenn E Smith; David S Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-01-08       Impact factor: 4.673

Review 7.  Proton MRS in mild cognitive impairment.

Authors:  Kejal Kantarci
Journal:  J Magn Reson Imaging       Date:  2013-04       Impact factor: 4.813

8.  Brain β-amyloid load approaches a plateau.

Authors:  Clifford R Jack; Heather J Wiste; Timothy G Lesnick; Stephen D Weigand; David S Knopman; Prashanthi Vemuri; Vernon S Pankratz; Matthew L Senjem; Jeffrey L Gunter; Michelle M Mielke; Val J Lowe; Bradley F Boeve; Ronald C Petersen
Journal:  Neurology       Date:  2013-02-27       Impact factor: 9.910

9.  Alzheimer disease biomarkers and insights into mild cognitive impairment.

Authors:  David S Knopman
Journal:  Neurology       Date:  2013-02-06       Impact factor: 9.910

10.  MRI and MRS predictors of mild cognitive impairment in a population-based sample.

Authors:  Kejal Kantarci; Stephen D Weigand; Scott A Przybelski; Gregory M Preboske; V Shane Pankratz; Prashanthi Vemuri; Matthew L Senjem; Matthew C Murphy; Jeffrey L Gunter; Mary M Machulda; Robert J Ivnik; Rosebud O Roberts; Bradley F Boeve; Walter A Rocca; David S Knopman; Ronald C Petersen; Clifford R Jack
Journal:  Neurology       Date:  2013-06-12       Impact factor: 9.910

View more
  7 in total

1.  [MRI in dementia-type diseases].

Authors:  S V Bodea; R Mühl-Benninghaus
Journal:  Radiologe       Date:  2015-05       Impact factor: 0.635

2.  Effects of Moxa Cone Moxibustion Therapy on Cognitive Function and Brain Metabolic Changes in MCI Patients: A Pilot 1H-MRS Study.

Authors:  Wei Mai; Aizhen Zhang; Qiang Liu; Liying Tang; Yichen Wei; Jiahui Su; Gaoxiong Duan; Jinlong Teng; Xiucheng Nong; Bihan Yu; Chong Li; Lijuan Shao; Demao Deng; Shangjie Chen; Lihua Zhao
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702

3.  Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer's disease: Correlations and differences between the two methods.

Authors:  Artur M N Coutinho; Fábio H G Porto; Poliana F Zampieri; Maria C Otaduy; Tíbor R Perroco; Maira O Oliveira; Rafael F Nunes; Toulouse Leusin Pinheiro; Cassio M C Bottino; Claudia C Leite; Carlos A Buchpiguel
Journal:  Dement Neuropsychol       Date:  2015 Oct-Dec

4.  Lack of cognitive impairment in long-term survivors of colorectal cancer.

Authors:  Janette L Vardy; Gregory R Pond; Lucette A Cysique; Thomas M Gates; Jim Lagopoulos; Corrinne Renton; Louise M Waite; Ian F Tannock; Haryana M Dhillon
Journal:  Support Care Cancer       Date:  2022-04-14       Impact factor: 3.359

5.  Classification of Alzheimer's Disease Based on Deep Learning of Brain Structural and Metabolic Data.

Authors:  Huiquan Wang; Tianzi Feng; Zhe Zhao; Xue Bai; Guang Han; Jinhai Wang; Zongrui Dai; Rong Wang; Weibiao Zhao; Fuxin Ren; Fei Gao
Journal:  Front Aging Neurosci       Date:  2022-07-12       Impact factor: 5.702

Review 6.  Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease.

Authors:  Michael J Knight; Bryony McCann; Risto A Kauppinen; Elizabeth J Coulthard
Journal:  Front Aging Neurosci       Date:  2016-06-16       Impact factor: 5.750

7.  Application of modern neuroimaging technology in the diagnosis and study of Alzheimer's disease.

Authors:  Hong-Mei Zeng; Hua-Bo Han; Qi-Fang Zhang; Hua Bai
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.